2017
Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.
Thress K, Markovets A, Barrett J, Chmielecki J, Goldberg S, Shepherd F, Vowler S, Oxnard G. Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial. Journal Of Clinical Oncology 2017, 35: 9018-9018. DOI: 10.1200/jco.2017.35.15_suppl.9018.Peer-Reviewed Original ResearchMedian progression-free survivalPlasma EGFR mutationsDetectable EGFR mutationsEGFR mutationsClinical outcomesOverall median progression-free survivalResponse ratePlasma samplesDurable response rateHeterogeneous resistance mechanismsObjective response ratePositive advanced NSCLCProgression-free survivalEGFR-TKI therapyPredictors of outcomeTyrosine kinase inhibitorsBaseline genotypingEvaluable baselinePositive genotypingAdvanced NSCLCPositive NSCLCCombination therapyEGFR-TKIsOsimertinib therapyComplete clearance
2016
191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC
Peters S, Antonia S, Goldberg S, Heymach J, Kim E, Nakagawa K, Papadimitrakopoulou V, Mukhopadhyay P, McIntosh S, Rizvi N. 191TiP MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. Journal Of Thoracic Oncology 2016, 11: s139-s140. DOI: 10.1016/s1556-0864(16)30300-8.Peer-Reviewed Original Research